The situation of Covid-19 has become more and more complicated, while the World Health Organization (WHO) has called for increasing production of dexamethasone drugs with cautious recommendations.
Speaking at an online forum organized by the United Arab Emirates (UAE) on June 22, WHO Director General Tedros Adhanom Ghebreyesus called for the world to unite and take global leadership in dealing with the Covid-19 epidemic, after the number of cases surpassed 9 million yesterday. “The world’s biggest threat is not the new strain of corona virus (SARS-CoV-2) causing Covid-19. We cannot defeat the pandemic with the divided world. Politicizing the pandemic exacerbates it, ”AFP quoted him as saying.
While European countries continue to relax their epidemic control measures, Covid-19 cases around the world continue to increase, especially in North and South America. US President Donald Trump yesterday forecast that the number of deaths in the country could reach 150,000, while emphasizing that the number could have risen to 4 million without a countermeasure.
Meanwhile, many places are concerned about new infection clusters such as Melbourne (Australia), Lisbon (Portugal) and Beijing (China). AP quoted expert Michael Ryan, who is in charge of WHO’s emergency health program, said the record number of recorded Covid-19 cases showed that some of the most populous countries were approaching the peak of the epidemic. Prior to the news that the number of Covid-19 cases had increased due to extensive testing, Mr. Ryan denied this cause and pointed out that the epidemic situation was complicated because the number of hospitalizations and deaths were increasing.
Tedros urged countries to step up production of dexamethasone, a low-cost anti-inflammatory drug that helps reduce mortality in critically ill patients. About 2,000 Covid-19 patients used this drug in a study by the University of Oxford (UK) and the mortality rate decreased by 35% among the severe patients.
WHO emphasizes that this drug should be used only in critically or severely ill patients and under close observation at the hospital. “There is no evidence that this drug is effective against mild Covid-19 patients or has a preventive effect, even if it could be harmful,” Tedros warned and urged suppliers to ensure that quality assurance because of the high risk of fake or poor quality products being marketed.